Anthropic has acquired stealth biotech startup Coefficient Bio in an all-stock transaction valued at over $400 million, marking a significant step in its expansion into healthcare and life sciences.
Founded less than a year ago, Coefficient Bio operated largely in stealth mode for 7–8 months and had yet to launch a public product or generate revenue. Despite this, the startup built a highly specialized team of computational biology experts, many of whom previously worked at Genentech. Their expertise in biological foundation models and biomolecule design made them a valuable acquisition in the competitive AI-biotech talent landscape.
The company was founded by Samuel Stanton and Nathan C. Frey, both of whom had experience in computational drug discovery. Their work focused on using AI to streamline scientific experimentation and improve efficiency in drug development and biological research.
Following the acquisition, Coefficient Bio’s team—comprising around 10 specialists—is expected to join Anthropic’s healthcare and life sciences division, contributing to the development of advanced AI-driven research tools.
This move builds on Anthropic’s broader push into the life sciences sector, including the launch of its Claude for Life Sciences initiative. By integrating Coefficient Bio’s capabilities, the company aims to strengthen its position in the rapidly growing drug discovery market, which is estimated to exceed $100 billion.
The acquisition also places Anthropic in closer competition with major players such as Google DeepMind, NVIDIA, and OpenAI, all of whom are actively investing in AI-driven healthcare solutions.
As AI continues to reshape scientific research, Anthropic’s investment signals a strategic shift toward integrating advanced AI models into real-world applications such as drug discovery, positioning the company at the intersection of artificial intelligence and biotechnology innovation.
